Advertisement

Topics

Exelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of Indebtedness

08:00 EDT 29 Jun 2017 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
- Retiring Notes early saves $12 million in interest expense, net of termination fee - - In 2016 and 2017, Exelixis retired more than $490 million of debt - Exelixis, Inc. (Nasdaq:EXEL) today announced that i...

Other Sources for this Article

Exelixis, Inc.
Susan Hubbard, 650-837-8194
EVP, Public Affairs &
Investor Relations
shubbard@exelixis.com
or
For Exelixis, Inc.
Hal Mackins, 415-994-0040
hal@torchcomllc.com

NEXT ARTICLE

More From BioPortfolio on "Exelixis Repays Deerfield Notes One Year Ahead of Maturity Date, Addressing Last Major Source of Indebtedness"

Quick Search
Advertisement
 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...